RADX Stock Summary and Trading Ideas (Radiopharm Theranostics Limited - American Depositary Shares | NASDAQ:RADX)

Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.

Radiopharm Theranostics Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol RADX.

As of December 17, 2025, RADX stock price declined to $5.34 with 567,642 million shares trading.

RADX has a beta of 0.44, meaning it tends to be less sensitive to market movements. RADX has a correlation of 0.00 to the broad based SPY ETF.

RADX has a market cap of $41.54 million. This is considered a Sub-Micro Cap stock.

RADX has outperformed the market in the last year with a price return of +11.9% while the SPY ETF gained +11.8%. However, in the short term, RADX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -23.7% vs +2.0% return in SPY. But in the last 2 weeks, RADX shares have fared better than the market returning +26.2% compared to SPY -1.5%.

RADX support price is $5.30 and resistance is $6.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RADX shares will trade within this expected range on the day.